The analysis of the influence of spironolactone and its combination with trimetazidine treatment on clinical symptoms, and cardiac structure and function parameters in chronic heart failure with preserved ejection fraction patients

Authors

  • Лариса Михайлівна Єна D. F. Chebotarev State Institute of Gerontology NAMS of Ukraine Vyshgorodska str., 67, Kyiv, Ukraine, 04114, Ukraine https://orcid.org/0000-0001-9676-2250
  • Віталіна Олександрівна Ярош D.F. Chebotarev State Institute of Gerontology NAMS of Ukraine, Vyshgorodska str., 67, Kyiv, Ukraine, 04114, Ukraine https://orcid.org/0000-0002-4636-1616

DOI:

https://doi.org/10.15587/2519-4798.2016.87853

Keywords:

chronic heart failure with preserved ejection fraction, Spironolactone, Trimetazidine, diastolic disfuncton

Abstract

Aim. To study clinical symptoms dynamics, functional condition, the quality of life, and cardiac structure and function in patients having chronic heart failure with preserved ejection fraction (CHFPEF) after Spironolactone (S) and its combination with Trimetazidine (S+T) therapy.

Methods. 90 patients (aged from 60-74 years) suffering from hypertension with CHFPEF were examined using echocardiography, 6-minute walk test (SMWT), and the Minnesota living with heart failure questionnaire (MLHF) before, 6 and 12 months later after the standard therapy (K), standard with S use, and standard with S+T use.

Results. On the clinical symptoms positive dynamics background, the distance of SMWT significantly increased on 26±9 m in К, 36±9 m in S, and 55±8 m in S+T; according to the MLHF, the number of points decreased: on 9,9±2,4, 17,1±2,6 і 12,9±2,3, respectively. A statistically significant decrease in left ventricular mass (LV) was on 10,4±4,4 g in К, 22,1±7,9 g in S, and 28,6±7,7g in S+T, but only in S and in S+T it accompanied by left atrium decrease – on 9,3±2,4 ml and 8,8±2,3 ml (p<0,05), respectively. The use of S and S+T led to the more expressed E/E reduction – on 2,3±0,8 cu and 2,8±0,5 cu (all р <0,05), respectively, comparing to K – on 1,2±0,4 cu (p>0,05). Systolic blood pressure (BP) in the pulmonary artery significantly decreased only in S and S+T. More distinct dynamics of echocardiographic parameters in case of S and S+T partly can be associated with more significant decrease in systolic and diastolic BP.

Conclusion. Adding Spironolactone and its combination with Trimetazidine to the standard therapy of CHFPEF patients leads to the more significant functional condition positive dynamics, the quality of life, more expressed LV hypertrophy regression, system BP and BP in the pulmonary artery decrease, the improvement of LV diastolic functon

Author Biographies

Лариса Михайлівна Єна, D. F. Chebotarev State Institute of Gerontology NAMS of Ukraine Vyshgorodska str., 67, Kyiv, Ukraine, 04114

Doctor of Medical Science, Professor, Head of Department

Department of Clinical and Epidemiological Cardiology

Віталіна Олександрівна Ярош, D.F. Chebotarev State Institute of Gerontology NAMS of Ukraine, Vyshgorodska str., 67, Kyiv, Ukraine, 04114

Postgraduate student

Department of Clinical and Epidemiological Cardiology

References

  1. Becher, P., Fluschnik, N., Blankenberg, S. et. al. (2015). Challenging aspects of treatment strategies in heart failure with preserved ejection fraction: Why did recent clinical trials fail? World Journal of Cardiology, 7 (9), 544–554.
  2. Steinberg, B. A., Zhao, X., Heidenreich, P. A., Peterson, E. D., Bhatt, D. L. et. al. (2012). Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction: Prevalence, Therapies, and Outcomes. Circulation, 126 (1), 65–75. doi: 10.1161/circulationaha.111.080770
  3. Paulus, W. J., Tschope, C. (2013). A Novel Paradigm for Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 62 (4), 263–271. doi: 10.1016/j.jacc.2013.02.092
  4. Yusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J. et. al. (2003). Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. The Lancet, 362 (9386), 777–781. doi: 10.1016/s0140-6736(03)14285-7
  5. Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R. et. al. (2008). Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. New England Journal of Medicine, 359 (23), 2456–2467. doi: 10.1056/nejmoa0805450
  6. Cleland, J. G. F. (2006). The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal, 27 (19), 2338–2345. doi: 10.1093/eurheartj/ehl250
  7. Shah, S. J., Kitzman, D. W., Borlaug, B. A., van Heerebeek, L., Zile, M. R., Kass, D. A., Paulus, W. J. (2016). Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction. Circulation, 134 (1), 73–90. doi: 10.1161/circulationaha.116.021884
  8. Kurrelmeyer, K. M., Ashton, Y., Xu, J., Nagueh, S. F., Torre-Amione, G., Deswal, A. (2014). Effects of Spironolactone Treatment in Elderly Women With Heart Failure and Preserved Left Ventricular Ejection Fraction. Journal of Cardiac Failure, 20 (8), 560–568. doi: 10.1016/j.cardfail.2014.05.010
  9. Edelmann, F., Wachter, R., Schmidt, A. G., Kraigher-Krainer, E., Colantonio, C., Kamke, W. et. al. (2013). Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction. JAMA, 309 (8), 781. doi: 10.1001/jama.2013.905
  10. Shah, A. M., Shah, S. J., Anand, I. S., Sweitzer, N. K., O’Meara, E. et. al. (2013). Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: Baseline Findings From the Echocardiographic Study of the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. Circulation: Heart Failure, 7 (1), 104–115. doi: 10.1161/circheartfailure.113.000887
  11. Jena, L. M., Ghrushovsjka, V. M. (2010). Ghipertonichna khvoroba ta diastolichna dysfunkcija v starechomu vici: vplyv tryvaloji kombinovanoji antyghipertenzyvnoji ta metabolichnoji terapiji [Arterial hypertension and diastolic dysfunction in old age: the impact of long lasting antihypertensive and metabolic therapy combination]. Heart and Vessels, 2, 90–96.
  12. Winter, J. L., Castro, P. F., Quintana, J. C., Altamirano, R., Enriquez, A., Verdejo, H. E. et. al. (2014). Effects of Trimetazidine in Nonischemic Heart Failure: A Randomized Study. Journal of Cardiac Failure, 20 (3), 149–154. doi: 10.1016/j.cardfail.2014.01.004
  13. Voronkov, L. Gh., Amosova, K. M., Baghrij, A. E. et. al. (2014). Rekomendaciji Asociaciji kardiologhiv Ukrajiny ta Ukrajinsjkoji asociaciji fakhivciv iz sercevoji nedostatnosti z diaghnostyky ta likuvannja khronichnoji sercevoji nedostatnosti [The recommendations of the Association of Cardiologists of Ukraine and the Ukrainian Association of specialists in heart failure diagnosis and treatment of chronic heart failure]. Ukrainian Journal of Cardiology, 44.
  14. Parajon, T., Lupon, J., Gonzalez, B., Urrutia, A., Altimir, S., Coll, R. et. al. (2004). Use of the “Minnesota Living With Heart Failure” Quality of Life Questionnaire in Spain. Revista Española de Cardiología (English Edition), 57 (2), 155–160. doi: 10.1016/s1885-5857(06)60104-7
  15. Waggoner, A. D., Bierig, S. M. (2001). Tissue Doppler imaging: A useful echocardiographic method for the cardiac sonographer to assess systolic and diastolic ventricular function. Journal of the American Society of Echocardiography, 14 (12), 1143–1152. doi: 10.1067/mje.2001.115391
  16. Radchenko, Gh. D., Sirenko, Ju. M. (2010). Ghipertrofija livogho shlunochka: vyznachennja, metody ocinky, mozhlyvosti reghresuvannja [Left ventricular hypertrophy: definition, evaluation methods, the possibility of regression]. Arterial Hypertension, 4 (12), 82–90.
  17. McLaughlin, V., Archer, S., Badesch, D. et. al. (2009). ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. Circulation, 119, 2250–2294.
  18. Butler, J., Fonarow, G. C., Zile, M. R., Lam, C. S., Roessig, L., Schelbert, E. B. et. al. (2014). Developing Therapies for Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2 (2), 97–112. doi: 10.1016/j.jchf.2013.10.006
  19. Pandey, A., Garg, S., Matulevicius, S. A., Shah, A. M., Garg, J., Drazner, M. H. et. al. (2015). Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta-Analysis and Systematic Review. Journal of the American Heart Association, 4 (10), e002137. doi: 10.1161/jaha.115.002137
  20. Kosmala, W., Rojek, A., Przewlocka-Kosmala, M., Wright, L., Mysiak, A., Marwick, T. H. (2016). Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 68 (17), 1823–1834. doi: 10.1016/j.jacc.2016.07.763
  21. Patel, D. A., Lavie, C. J., Milani, R. V., Ventura, H. O. (2011). Left Atrial Volume Index Predictive of Mortality Independent of Left Ventricular Geometry in a Large Clinical Cohort With Preserved Ejection Fraction. Mayo Clinic Proceedings, 86 (8), 730–737. doi: 10.4065/mcp.2010.0682
  22. Goliasch, G., Zotter-Tufaro, C., Aschauer, S., Duca, F., Koell, B., Kammerlander, A. A. et. al. (2015). Outcome in Heart Failure with Preserved Ejection Fraction: The Role of Myocardial Structure and Right Ventricular Performance. PLOS ONE, 10 (7), e0134479. doi: 10.1371/journal.pone.0134479

Downloads

Published

2016-12-28

How to Cite

Єна, Л. М., & Ярош, В. О. (2016). The analysis of the influence of spironolactone and its combination with trimetazidine treatment on clinical symptoms, and cardiac structure and function parameters in chronic heart failure with preserved ejection fraction patients. ScienceRise: Medical Science, (12 (8), 57–63. https://doi.org/10.15587/2519-4798.2016.87853

Issue

No. 12 (8) (2016)

Section

Medical Science

License

Copyright (c) 2016 Лариса Михайлівна Єна, Віталіна Олександрівна Ярош

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.